Barclays Maintains Overweight on Lumexa Imaging Hldgs, Lowers Price Target to $15
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Andrew Mok maintains Lumexa Imaging Hldgs (NASDAQ:LMRI) with a Overweight and lowers the price target from $23 to $15.
Barclays analyst Andrew Mok maintains Lumexa Imaging Hldgs (NASDAQ:LMRI) with a Overweight and lowers the price target from $23 to $15.